**Dataset for histopathology reports for prostatic carcinoma**

**Appendix C Reporting proforma for prostatic biopsies**

Surname……………………… Forenames………………….… Date of birth……….… Sex…..

Hospital………….……….…… Hospital no……………….….... NHS/CHI no……………...........

Date of receipt………….……. Date of reporting……….......... Report no…………..............….

Pathologist……….…………... Surgeon………………….…….

**Clinical information**

Pre biopsy PSA†: ………………ng/ml Not available □

Type of specimen: TRUS biopsy □ Transperineal □ Targeted □ Other (specify) □ ……..

**Nature of specimen(s) and core macroscopic items**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Right side  (specific locations below if applicable) | Number taken | Number received | Left side (specific locations below if applicable) | Number taken | Number received | Other (specific locations below if applicable) | Number  taken | Number received |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

**Core microscopic items**

Histological tumour type†: Acinar adenocarcinoma □

Prostatic ductal adenocarcinoma □

Small cell neuroendocrine carcinoma □

Other (specify) ………

Number of cores involved.

Right …….. out of ……. Location(s): ……………………………….......................

Left: ……... out of ……. Location(s): …………………………………....................

Other:…… out of ……. Location (s):……………………………………………….

Total number of cores involved: .….. out of ………...

\*Greatest **length** of cancer in one core: …….mm Location……… Not used\* □

\*Greatest **percentage** of cancer in one core: ….….% Location………. Not used\* □

\*Percentage of cancer in **all** cores: ….….% Not used\* □

Perineural invasion†: Not identified □ Present □

Invasion into adipose tissue: Not identified □ Present □

**Gleason score:** Not applicable\*\*□

Primary Gleason grade†: 3 □ 4 □ 5 □

Secondary Gleason grade†: 3 □ 4 □ 5 □

Gleason score: ………+……..=……………

Grade Group: 1 □ 2 □ 3 □ 4 □ 5□ Not applicable □

**SNOMED codes†: T………………….M…………………….**

**Signature of pathologist………………………………………… Date………….………..**

**Notes**

\* At least one of these data items should be recorded.

\*\* Post hormone or radiotherapy then Gleason score may not be reliable. Gleason score is not applicable to some morphological types (e.g. small cell neuroendocrine carcinoma).

† Data items that are currently part of the Cancer Outcomes and Services Dataset (COSD) version 6.

**Appendix D Reporting proforma for transurethral resections or enucleations   
of the prostate**

Surname……………………… Forenames………………….… Date of birth……….… Sex…..

Hospital………….……….…… Hospital no……………….….... NHS/CHI no……………...........

Date of receipt………….……. Date of reporting……….......... Report no…………..............….

Pathologist……….…………... Surgeon………………….…….

**Clinical information**

Pre biopsy PSA†: ………………………ng/ml Not available □

**Type of specimen**

TURP □ Enucleation □

**Microscopic items**

Histological tumour type†:

Acinar adenocarcinoma □

Prostatic ductal adenocarcinoma □

Small cell neuroendocrine carcinoma □

Other (specify) ………

% of prostatic tissue involved by tumour based on area†: ……….% Not used\* □

% of prostatic tissue involved by tumour based on number of chips†: ………% Not used\* □

**Gleason score:**  Not applicable\*\* □

Primary Gleason grade†: 2 □ 3 □ 4 □ 5 □

Secondary Gleason grade†: 2 □ 3 □ 4 □ 5 □

Gleason score: ………+……..=……………

Grade Group: 1 □ 2 □ 3 □ 4 □ 5 □ Not applicable\*\* □

T category (TNM 2009): T1a □ (Incidental carcinoma in 5% or less of tissue resected)

T1b □ (Incidental carcinoma over 5% of tissue resected)

T3a □ (Bladder neck or EPE)

**SNOMED codes†: T………………….M……………………….**

**Signature of pathologist………………………………………… Date………….………..**

**Notes**

\* At least one of these data items should be recorded. For enucleation specimens then area method should be used.

\*\* Post hormone or radiotherapy then Gleason score may not be reliable. Gleason score is not applicable to some morphological types (e.g. small cell neuroendocrine carcinoma).

† Data items which are currently part of the Cancer Outcomes and Services Dataset (COSD) version 6.

**Appendix E Reporting proforma for radical prostatectomies**

Surname……………………… Forenames………………….… Date of birth……….… Sex…..

Hospital………….……….…… Hospital no……………….….... NHS/CHI no……………...........

Date of receipt………….……. Date of reporting……….......... Report no…………..............….

Pathologist……….…………... Surgeon………………….…….

**Clinical information**

Pre biopsy serum PSA† ‡,:………………………ng/ml Not available □

**Nature of specimen(s) and macroscopic items**

Specimen weight (i.e. prostate without seminal vesicles) ‡: ……. g

Seminal vesicles‡: Present (partially or completely resected) □ Absent □

(If present, Laterality: Left □ Right □ Bilateral □)

Lymph nodes‡: Present □ Absent □

(If present, Laterality‡: Left □ Right □ Preprostatic □ )

**Core Microscopic items**

Histological tumour type†‡:

Acinar adenocarcinoma □

Prostatic ductal adenocarcinoma □

Small cell neuroendocrine carcinoma □

Other (specify) ………

No tumour □

**Gleason score:**  Not applicable\*\* □

Primary Gleason grade†‡: 2 □ 3 □ 4 □ 5 □

Secondary Gleason grade†‡: 2 □ 3 □ 4 □ 5 □

Tertiary Gleason grade (<5%)†‡: 3 □ 4 □ 5 □ Not applicable □

Gleason score: ………+……..=……………

Grade Group: 1 □ 2 □ 3 □ 4 □ 5 □ Not applicable\*\* □

Location of dominant tumour: …………….

Extraprostatic extension (EPE) pT3a†‡: Not identified □ Present □ Indeterminate □

*If EPE*: Location of EPE:……………..

*If EPE:* Extent of EPE‡: Focal □ Established □

Bladder neck (pT3a): Involved □ Not involved □ Not applicable □

Seminal Vesicles (pT3b) †‡: Involved □ Not involved □ Not applicable □

Margin status†‡: Involved □ Not involved □ Indeterminate □

*If involved:* Extent (total): <3 mm □ > or = 3 mm □

*If involved:* Location: Apical □ Bladder neck □ Circumferential □

*If circumferential margin involved*‡*:* Intraprostatic □ Extraprostatic □

*If circumferential margin involved:* Location*(s)…………………….*

Lymphovascular invasion‡: Not identified □ Present □

**Regional lymph node status**

Number of lymph nodes examined†‡:……………

Number of positive lymph nodes†‡: ……………….

Maximum dimension of largest deposit‡:…………..mm

Primary tumour – T category (TNM 2009) †‡

pT0 □ (no tumour)

pT2 □ (organ confined)

pT3a □ (EPE, bladder neck)

pT3b □ (SV positive)

pT4 □ (involves other organs)

Regional lymph nodes – N category (TNM 2009) †‡

pNx □

pN0 □

pN1 □

**Stage pT……….. pN……………..**

**SNOMED codes**†**: T………………….M……………………….**

**Signature of pathologist………………………………………… Date………….………..**

**Notes**

\*\* Post hormone or radiotherapy then Gleason score may not be reliable. Gleason score is not applicable to some morphological types (e.g. small cell neuroendocrine carcinoma).

† Data items which are currently part of the Cancer Outcomes and Services Dataset (COSD) version 6.

‡ Data items which are used in version 1.0 of the ICCR Prostate Cancer (Radical Prostatectomy) dataset.